Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Emcure Pharmaceuticals Ltd. (EMCURE.NS)
Pune, IN
Emcure Pharmaceuticals Limited is committed to providing high-quality, cost-effective healthcare solutions to a global market. The company boasts a diverse product lineup spanning numerous medical fields, such as women's health (gynecology), anti-infectives, pain relief, nutritional supplements (vitamins, minerals, and nutrients), hematology, oncology, respiratory treatments, HIV antivirals, gastrointestinal remedies, anti-diabetics, neurological medications, and cardiovascular therapies. Notable brand names under their umbrella include Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym. Founded in 1981, Emcure Pharmaceuticals Limited is headquartered in Pune, India.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.22% | -1.56% | +3.55% | +13.59% | +23.78% | +21.50% | +59.81% | +21.95% | +21.95% | +21.95% | +21.95% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 5 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+17.9% ★ Q1'26: +21.7% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+11,241.9% ★ Q1'26: +27.9% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+3.9% Q1'26: +5.2% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+14.9% ★ Q1'26: +15.4% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+15.8% ★ Q1'26: +17.1% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+1.3% Q1'26: +0.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.11× Q1'26: 0.78× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2025 actual |
Mar 2026 6 Rev. Ana. 5 EPS Ana. |
Mar 2027 5 Rev. Ana. 6 EPS Ana. |
Mar 2028 6 Rev. Ana. 6 EPS Ana. |
Mar 2029 5 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
78.08B
est: 78.47B (-0.5%)
|
91.56B
91.27B – 92.05B
+16.7% YoY
|
104.32B
103.83B – 105.03B
+13.9% YoY
|
116.77B
112.72B – 119.69B
+11.9% YoY
|
128.62B
125.98B – 130.72B
+10.1% YoY
|
| EBITDA |
14.95B
est: 13.37B (+11.9%)
|
15.60B
15.55B – 15.68B
+16.7% YoY
|
17.77B
17.69B – 17.89B
+13.9% YoY
|
19.90B
19.21B – 20.39B
+11.9% YoY
|
21.91B
21.46B – 22.27B
+10.1% YoY
|
| EBIT |
11.11B
est: 11.44B (-2.8%)
|
13.35B
13.31B – 13.42B
+16.7% YoY
|
15.21B
15.14B – 15.31B
+13.9% YoY
|
17.02B
16.43B – 17.45B
+11.9% YoY
|
18.75B
18.37B – 19.06B
+10.1% YoY
|
| Net Income |
6.81B
est: 6.96B (-2.2%)
|
9.75B
9.07B – 10.19B
+40.0% YoY
|
12.16B
11.67B – 12.45B
+24.7% YoY
|
14.91B
13.79B – 15.86B
+22.6% YoY
|
17.67B
17.20B – 18.05B
+18.6% YoY
|
| SGA |
8.38B
est: 13.61B (-38.5%)
|
15.88B
15.83B – 15.97B
+16.7% YoY
|
18.10B
18.01B – 18.22B
+13.9% YoY
|
20.26B
19.55B – 20.76B
+11.9% YoY
|
22.31B
21.85B – 22.68B
+10.1% YoY
|
| EPS |
0.43
est: 36.74 (-98.8%)
|
51.45
47.85 – 53.75
+40.0% YoY
|
64.14
61.60 – 65.67
+24.7% YoY
|
78.64
72.75 – 83.66
+22.6% YoY
|
93.25
90.76 – 95.23
+18.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-11 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-08 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-07 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-06 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Satish Ramanlal Mehta | Chief Executive Officer, MD & Executive Director | 256M | male |
| Mukund Keshao Gurjar | Chief Scientific Officer & Whole-Time Director | 62M | — |
| Namita Vikas Thapar | Executive Director of India Business & Whole-Time Director | 48M | female |
| Sunil Rajanikant Mehta | Executive Director of Projects & Whole-Time Director | 48M | male |
| Samit Satish Mehta | President of Operations & Whole-Time Director | 34M | male |
| Tajuddin Sabir Shaikh | Chief Financial Officer | 17M | male |
| Vikas Madan Thapar | President of Corporate Development, Strategy & Finance | 4M | male |
| Rajesh Nair | President of HR | — | male |
| Naveen Soni | Director of Corporate Communications & Public Relations | — | male |
| Amruta Jana Yangalwar | Company Secretary & Compliance Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for EMCURE.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
